Enhanced antimicrobial activity of engineered human lysozyme
about
Crystal Structure of a Charge Engineered Human Lysozyme Having Enhanced Bactericidal ActivityThe selective interaction between silica nanoparticles and enzymes from molecular dynamics simulationsPolyelectrolyte properties of filamentous biopolymers and their consequences in biological fluids.Bioengineered lysozyme in combination therapies for Pseudomonas aeruginosa lung infectionsA high-throughput screen for antibiotic drug discoveryThe Natural Antimicrobial Enzyme Lysozyme is Up-Regulated in Gastrointestinal Inflammatory Conditions.Fusion with a cell wall binding domain renders autolysin LytM a potent anti-Staphylococcus aureus agent.Discovery of novel S. aureus autolysins and molecular engineering to enhance bacteriolytic activity.Engineering Escherichia coli for soluble expression and single step purification of active human lysozyme.The particle in the spider's web: transport through biological hydrogels.Targeting the permeability barrier and peptidoglycan recycling pathways to disarm Pseudomonas aeruginosa against the innate immune system.Properties and mutation studies of a bacteriophage-derived chimeric recombinant staphylolytic protein P128: Comparison to recombinant lysostaphin.Bioengineered lysozyme reduces bacterial burden and inflammation in a murine model of mucoid Pseudomonas aeruginosa lung infection.NIR-Mediated Nanohybrids of Upconversion Nanophosphors and Fluorescent Conjugated Polymers for High-Efficiency Antibacterial Performance Based on Fluorescence Resonance Energy Transfer.Evolutionary trade-offs associated with loss of PmrB function in host-adapted Pseudomonas aeruginosa.
P2860
Q27667276-310064E3-C59E-45B7-98A8-E77ECA399D36Q28543130-BF13DE87-BC23-4959-AE06-A6E75FCBE080Q33563964-6E3BD0BE-C66D-42D0-A03E-C6A85D634CE2Q33728266-37FF651B-4159-4283-9E00-DBAE1910B4E5Q33857043-5BAF4F33-1D9E-4992-8CF7-EFB5A209DA5BQ34533697-E67A383A-3A15-494E-AB59-B18F98C1B64BQ35653429-0F194B8B-51CA-41AB-AD80-A267124C1FB3Q35842148-38F75758-F086-405D-957D-2205268C0888Q36675070-2D3EA93F-C125-4B2B-B8A9-61E3F48D0215Q39350747-DF992FC2-A8C8-437A-BF21-CB960DF7BBBEQ40120435-31F0CFC4-A037-4C2C-B1D8-D46C34038755Q42126654-627A8BB6-4ACF-4B67-9E4D-836EBCC349BFQ42930592-58F96CB9-0275-420F-B456-59F44F87ECC7Q46449440-AE6B1609-5632-421F-82FA-713A811B356AQ55486863-0DAD59E3-A25F-47C4-A1DD-01D8B0165F5D
P2860
Enhanced antimicrobial activity of engineered human lysozyme
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Enhanced antimicrobial activity of engineered human lysozyme
@ast
Enhanced antimicrobial activity of engineered human lysozyme
@en
type
label
Enhanced antimicrobial activity of engineered human lysozyme
@ast
Enhanced antimicrobial activity of engineered human lysozyme
@en
prefLabel
Enhanced antimicrobial activity of engineered human lysozyme
@ast
Enhanced antimicrobial activity of engineered human lysozyme
@en
P2093
P2860
P356
P1433
P1476
Enhanced antimicrobial activity of engineered human lysozyme
@en
P2093
Avinash Gill
Charlotte C Teneback
Jenna L Bement
John W Lamppa
Laurie W Leclair
Thomas C Scanlon
P2860
P304
P356
10.1021/CB1001119
P577
2010-09-01T00:00:00Z